User profiles for "author:Peter van der Meer"

peter van der meer

Cardiologist, University Medical Center Groningen
Verified email at umcg.nl
Cited by 53393

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …

S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Anemia and mortality in heart failure patients: a systematic review and meta-analysis

HF Groenveld, JL Januzzi, K Damman… - Journal of the American …, 2008 - jacc.org
Objectives: The aim of this study was to assess the effect of anemia on mortality in chronic
heart failure (CHF). Background: Anemia is frequently observed in patients with CHF, and …

A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction

J Tromp, W Ouwerkerk, DJ van Veldhuisen, HL Hillege… - Heart Failure, 2022 - jacc.org
Objectives This study sought to estimate and compare the aggregate treatment benefit of
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Semaglutide in patients with heart failure with preserved ejection fraction and obesity

MN Kosiborod, SZ Abildstrøm, BA Borlaug… - … England Journal of …, 2023 - Mass Medical Soc
Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid

P Garcia-Pavia, F Aus dem Siepen… - … England Journal of …, 2023 - Mass Medical Soc
Background Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal
disease caused by misfolded transthyretin. Despite advances in slowing disease …

[HTML][HTML] Iron deficiency in chronic heart failure: an international pooled analysis

IJT Klip, J Comin-Colet, AA Voors, P Ponikowski… - American heart …, 2013 - Elsevier
BACKGROUND: Iron deficiency (ID) is an emerging problem in patients with chronic heart
failure (HF) and can be a potential therapeutic target. However, not much is known about the …

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

RA de Boer, DJA Lok, T Jaarsma… - Annals of …, 2011 - Taylor & Francis
Aims. Galectin-3 is an emerging biomarker which has been studied in relatively small heart
failure (HF) cohorts with predominantly systolic HF. We studied the prognostic value of base …

[HTML][HTML] Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

DJA Lok, P Van Der Meer, PWBA de la Porte… - Clinical research in …, 2010 - Springer
Aims Biomarkers are increasingly being used in the management of patients with chronic
heart failure (HF). Galectin-3 is a recently developed biomarker associated with fibrosis and …

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

P Ponikowski, BA Kirwan, SD Anker, T McDonagh… - The Lancet, 2020 - thelancet.com
Background Intravenous ferric carboxymaltose has been shown to improve symptoms and
quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate …